Medexus Pharmaceuticals Inc.
MEDXF
$2.24
-$0.031-1.37%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -17.46% | 14.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.46% | 14.03% | |||
| Cost of Revenue | -23.98% | 22.96% | |||
| Gross Profit | -12.41% | 7.94% | |||
| SG&A Expenses | 10.97% | 13.24% | |||
| Depreciation & Amortization | 38.72% | 11.42% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.45% | 18.05% | |||
| Operating Income | -107.67% | -7.78% | |||
| Income Before Tax | -186.25% | 251.46% | |||
| Income Tax Expenses | -240.14% | 121.27% | |||
| Earnings from Continuing Operations | -175.44% | 566.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -175.44% | 566.36% | |||
| EBIT | -107.67% | -7.78% | |||
| EBITDA | -62.02% | -2.45% | |||
| EPS Basic | -162.96% | 560.00% | |||
| Normalized Basic EPS | -88.79% | -53.44% | |||
| EPS Diluted | -162.96% | 560.00% | |||
| Normalized Diluted EPS | -88.79% | -53.44% | |||
| Average Basic Shares Outstanding | 19.97% | 0.52% | |||
| Average Diluted Shares Outstanding | 19.97% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||